Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
Abstract The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) offer expedited regulatory approval programs for drugs with high potential patient value applicable at different stages leading to marketing authorization: (i) drug development (fast track designation (FTD), b...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2023-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|